Literature DB >> 20201884

PI3K kinase and scaffold functions in heart.

Federico Damilano1, Alessia Perino, Emilio Hirsch.   

Abstract

Signal transduction events are key modulators of cellular function and, in the cardiovascular system, an emerging role is played by phosphoinositide 3-kinases (PI3Ks), a family of enzymes containing a 3-phosphorylated phosphoinositide that produce lipid second messengers. In the heart, multiple PI3K isoforms are expressed, but play potentially distinct roles. Among cardiac PI3Ks, PI3Kalpha is triggered by tyrosine kinase receptors and plays a role in adaptive hypertrophy, while PI3Kgamma is triggered by G protein-coupled receptors and is involved in maladaptive heart remodeling. This view has been recently complicated by the finding that PI3Ks can also be involved in protein-protein interactions and affect signaling independently of their kinase activity. This review will thus focus on the effects of these multiple signaling events, with particular emphasis on their involvement in cardiac hypertrophy and failure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20201884     DOI: 10.1111/j.1749-6632.2009.05081.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  22 in total

1.  A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP 1 and phosphatidylinositol 3-kinase signals in human arterial endothelial cells.

Authors:  Lindsay S Wilson; George S Baillie; Lisa M Pritchard; Bibiana Umana; Anna Terrin; Manuela Zaccolo; Miles D Houslay; Donald H Maurice
Journal:  J Biol Chem       Date:  2011-03-10       Impact factor: 5.157

2.  p87 and p101 subunits are distinct regulators determining class IB phosphoinositide 3-kinase (PI3K) specificity.

Authors:  Aliaksei Shymanets; Kirsten Bucher; Sandra Beer-Hammer; Christian Harteneck; Bernd Nürnberg
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

3.  Small GTPase Rab8a-recruited Phosphatidylinositol 3-Kinase γ Regulates Signaling and Cytokine Outputs from Endosomal Toll-like Receptors.

Authors:  Adam A Wall; Lin Luo; Yu Hung; Samuel J Tong; Nicholas D Condon; Antje Blumenthal; Matthew J Sweet; Jennifer L Stow
Journal:  J Biol Chem       Date:  2017-01-27       Impact factor: 5.157

Review 4.  Treatment of HER2-positive breast cancer: current status and future perspectives.

Authors:  Carlos L Arteaga; Mark X Sliwkowski; C Kent Osborne; Edith A Perez; Fabio Puglisi; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2011-11-29       Impact factor: 66.675

5.  Ablation of phospholamban and sarcolipin results in cardiac hypertrophy and decreased cardiac contractility.

Authors:  Mayilvahanan Shanmugam; Shumin Gao; Chull Hong; Nadezhda Fefelova; Martha C Nowycky; Lai-Hua Xie; Muthu Periasamy; Gopal J Babu
Journal:  Cardiovasc Res       Date:  2010-09-10       Impact factor: 10.787

6.  Inhibition of the α-Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic.

Authors:  Tao Yang; David F Meoli; Javid Moslehi; Dan M Roden
Journal:  J Pharmacol Exp Ther       Date:  2018-03-21       Impact factor: 4.030

Review 7.  Scaffolding Function of PI3Kgamma Emerges from Enzyme's Shadow.

Authors:  Maradumane L Mohan; Sathyamangla V Naga Prasad
Journal:  J Mol Biol       Date:  2017-02-06       Impact factor: 5.469

Review 8.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

9.  Phosphoinositide 3-kinase γ inhibits cardiac GSK-3 independently of Akt.

Authors:  Maradumane L Mohan; Babal K Jha; Manveen K Gupta; Neelakantan T Vasudevan; Elizabeth E Martelli; John David Mosinski; Sathyamangla V Naga Prasad
Journal:  Sci Signal       Date:  2013-01-22       Impact factor: 8.192

Review 10.  Phosphatidylinositol-3,4,5-trisphosphate: tool of choice for class I PI 3-kinases.

Authors:  Rachel Schnur Salamon; Jonathan M Backer
Journal:  Bioessays       Date:  2013-07       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.